Angiochem to announce clinical study results of ANG1005 drug

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009. In addition to poster presentations, ANG1005 and Angiochem’s EPiC platform will be the subject of a Society for Neurosciences-sponsored press conference, entitled “Crossing the Blood-Brain Barrier.” Angiochem will also be sponsoring a scientific symposia discussing new therapeutic approaches to crossing the blood-brain barrier.

ANG1005 is a novel, next-generation taxane derivative, targeting the LRP pathway to cross the blood-brain barrier and reach therapeutic concentrations in the brain. ANG1005 is in two separate Phase 1/2 clinical studies in patients with brain cancers and cancer metastases. The drug was created with Angiochem’s Engineered Peptide Compound (EPiC) platform which harnesses the naturally-occurring LRP (low-density lipoprotein receptor-related protein) receptors on the surface of the blood-brain barrier.